Drugs / AFN50
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07448298 | Mar 2026 → Feb 2028 expected | — | Beijing Boren Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT07408336 | Feb 2026 → Feb 2028 expected | autoimmune disease | AlphaNa Bioscience Company Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AFN50 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07448298 ↗ |
| Route | Intravenous | “Intravenous infusion therapy.” NCT07408336 ↗ |